How many deferred share units did MustGrow Biologics (MGROF) grant and to whom?

The board approved the grant of 1,126,954 deferred share units (DSUs) to directors (excluding the Chief Executive Officer and Chief Operating Officer) and to Tyler Reinheimer, effective September 3, 2026, under the Company’s omnibus equity incentive plan.

How are the MustGrow Biologics (MGROF) deferred share units settled?

On settlement, each DSU entitles the holder to receive one common share of MustGrow Biologics or a cash payment equivalent, at the discretion of the Company. The settlement form is therefore not fixed in advance.

MustGrow Announces Officer Appointment and Grant of DSUs

Q: What management change did MustGrow Biologics (MGROF) announce on September 4, 2026?

MustGrow Biologics announced the appointment of Tyler Reinheimer, CPA, as Director, Finance of the Company. This leadership change is part of its broader corporate and compensation update disclosed on that date.

Q: When do the MustGrow Biologics (MGROF) DSUs granted on September 3, 2026 vest?

The DSUs granted by MustGrow Biologics will vest when the holder ceases to be a director, officer or employee of the Company or any of its affiliates, as applicable, rather than on a fixed calendar date.

MustGrow expands its finance leadership and awards deferred share units to directors and a new officer under its equity incentive plan.

Rhea-AI Impact

(Low)

Rhea-AI Sentiment

(Very Positive)

Rhea-AI Summary

MustGrow Biologics (MGROF) appointed Tyler Reinheimer, CPA, as Director, Finance and granted a total of 1,126,954 deferred share units (DSUs) to certain directors and Mr. Reinheimer, effective September 3, 2026.

The DSUs, issued under the omnibus equity incentive plan, vest when the holder leaves their role, and each DSU can be settled in one common share or an equivalent cash payment at the Company’s discretion.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

09/04/2026 - 07:00 AM

Saskatoon, Saskatchewan--(Newsfile Corp. - September 4, 2026) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow") today announced the appointment of Tyler Reinheimer, CPA, as Director, Finance of the Company and that the board of directors of the Company has authorized and approved the grant of a total of 1,126,954 deferred share units of the Company ("DSUs") to directors (excluding the Company's Chief Excutive Officer and Chief Operating Officer) and Mr. Reinheimer, effective September 3, 2026. This grant of DSUs is made pursuant to the Company's omnibus equity incentive plan.

The DSUs will vest when the holder ceases to be a director, officer or employee of the Company or any of its affiliates, as applicable. On settlement, each DSU will entitle the holder thereof to receive one common share in the capital of the Company, or a cash payment equivalent thereof at the discretion of the Company.

About MustGrow

MustGrow Biologics Corp. is a provider of innovative biological and regenerative agriculture solutions designed to support sustainable farming. The Company's technology is centered on harnessing the natural defense mechanisms and organic compounds found in mustard seed and formulating them into organic biofertility, biostimulant, and biocontrol products. These solutions are designed to protect soil health and the soil microbiome, support plant health, and contribute to global food security through more sustainable agricultural practices. In the United States, MustGrow's flagship biofertility product, TerraSante^TM, is registered, organically certified, and commercially sold in key agricultural states, including California. Outside of North America, MustGrow is focused on collaborating with leading global agriculture companies, such as Bayer AG in Europe, the Middle East, and Africa, to commercialize its wholly owned proprietary products and technologies. The Company is dedicated to driving shareholder value through the commercialization and expansion of its intellectual property portfolio, which includes approximately 110 issued and pending patents. MustGrow is publicly traded on the TSX Venture Exchange under the symbol MGRO and has approximately 70.4 million common shares issued and outstanding, and approximately 93.0 million shares on a fully diluted basis.

Contact Information

Corey Giasson
Director & CEO
Phone: +1-306-668-2652
info@mustgrow.ca

This release does not constitute an offer for sale of, nor a solicitation for offers to buy, any securities in the United States.

Neither the TSXV, nor their Regulation Services Provider (as that term is defined in the policies of the TSXV), nor the OTC Markets has approved the contents of this release or accepts responsibility for the adequacy or accuracy of this release.

Corporate Logo

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/312925

FAQ

What management change did MustGrow Biologics (MGROF) announce on September 4, 2026?

MustGrow Biologics announced the appointment of Tyler Reinheimer, CPA, as Director, Finance of the Company. This leadership change is part of its broader corporate and compensation update disclosed on that date.

When do the MustGrow Biologics (MGROF) DSUs granted on September 3, 2026 vest?

The DSUs granted by MustGrow Biologics will vest when the holder ceases to be a director, officer or employee of the Company or any of its affiliates, as applicable, rather than on a fixed calendar date.

Under which plan were the new MustGrow Biologics (MGROF) DSUs issued?

The 1,126,954 DSUs granted to certain directors and to Tyler Reinheimer were issued under MustGrow Biologics’ omnibus equity incentive plan, which governs equity-based compensation awards for eligible participants.